Sugi Predict

Sugi Predict / Targets / HEXA

HEXA

Beta-hexosaminidase subunit alpha · P06865 · HEXA on Sugi Atlas →

6,224 patent compounds predicted against HEXA, 4,111 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3290712 SCHEMBL3290712 0.78 15/20
SCHEMBL3292141 SCHEMBL3292141 0.78 15/20
SCHEMBL4408773 SCHEMBL4408773 1.00 14/20
Elinafide Elinafide (SCHEMBL19067) 0.90 14/20
Elinafide Elinafide (SCHEMBL1890262) 0.76 13/20
SCHEMBL3498787 SCHEMBL3498787 1.00 8/20
SCHEMBL4415942 SCHEMBL4415942 0.70 8/20
SCHEMBL3628166 SCHEMBL3628166 0.50 8/20
SCHEMBL4147996 SCHEMBL4147996 0.48 8/20
SCHEMBL1359352 SCHEMBL1359352 0.62 7/20
SCHEMBL1885367 SCHEMBL1885367 0.50 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1889973) 0.49 7/20
Pyrimethamine Pyrimethamine (SCHEMBL25129) 1.00 6/20
SCHEMBL626424 SCHEMBL626424 1.00 6/20
SCHEMBL1357011 SCHEMBL1357011 1.00 6/20
SCHEMBL4187947 SCHEMBL4187947 0.81 6/20
SCHEMBL2365312 SCHEMBL2365312 0.74 6/20
Pyrimethamine Pyrimethamine (SCHEMBL3671657) 0.73 6/20
SCHEMBL2363008 SCHEMBL2363008 0.71 6/20
SCHEMBL4448751 SCHEMBL4448751 0.71 6/20

Clinical trials — most relevant to HEXA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) PHASE3COMPLETED
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa PHASE3ACTIVE_NOT_RECRUITING
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease PHASE3COMPLETED
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) PHASE2COMPLETED
First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) PHASE1/PHASE2COMPLETED
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA PHASE1/PHASE2COMPLETED
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI PHASE2COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old PHASE2COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease PHASE2COMPLETED
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis PHASE1WITHDRAWN
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI PHASE1COMPLETED
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I PHASE1RECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
A Natural History of Late Onset Tay-Sachs Disease nanCOMPLETED
Translational Potential of ex Vivo Gene Therapy in GM2 Gangliosidosis nanNOT_YET_RECRUITING
Registry Gangliosidoses nanUNKNOWN
Non-invasive Functional Assessment and Pathogenesis of Morquio A nanRECRUITING
Natural History of Atypical Morquio A Disease nanCOMPLETED
BMN 110 US Expanded Access Program nanAPPROVED_FOR_MARKETING
Biomarker for Hurler Disease (BioHurler) nanWITHDRAWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Alglucosidase Alfa Temporary Access Program nanAPPROVED_FOR_MARKETING
Gene Therapy for Tay-Sachs Disease nanCOMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption nanUNKNOWN
Characterization of the Patient Population With Galactosialidosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HEXA binder may also engage these)

ProteinNameSimilarity
Q0V8R6 — 1.000 Q0V8R6 →
Q5RC84 — 1.000 Q5RC84 →
Q641X3 — 1.000 Q641X3 →
P29416 — 1.000 P29416 →
Q6AXR4 — 0.997 Q6AXR4 →
P20060 — 0.993 P20060 →
Q29548 — 0.991 Q29548 →
HEXB Beta-hexosaminidase subunit beta 0.991 landscape →
P49614 — 0.991 P49614 →
Q619W7 — 0.979 Q619W7 →
Q22492 — 0.978 Q22492 →
P31428 — 0.978 P31428 →
Q8K2I4 — 0.977 Q8K2I4 →
FUCA2 Plasma alpha-L-fucosidase 0.977 landscape →
Q2KIM0 — 0.976 Q2KIM0 →
P17164 — 0.976 P17164 →
Q8L7S6 — 0.976 Q8L7S6 →
Q99KR8 — 0.976 Q99KR8 →
Q5RFI5 — 0.976 Q5RFI5 →
A7WM73 — 0.975 A7WM73 →
P49010 — 0.975 P49010 →
Q95327 — 0.975 Q95327 →
Q99LJ1 — 0.975 Q99LJ1 →
Q29444 — 0.975 Q29444 →
Q6AYS4 — 0.975 Q6AYS4 →
P70699 — 0.975 P70699 →
DPEP1 Dipeptidase 1 0.974 landscape →
Q8BHN3 — 0.974 Q8BHN3 →
Q9SYK0 — 0.974 Q9SYK0 →
FUCA1 Tissue alpha-L-fucosidase 0.973 landscape →